Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent (subject; legally authorized representative) or signed conclusion of panel of independent medical doctors~2. Males and non-pregnant females aged 18 years or older at the IC date~3. Positive test for SARS-CoV2 nucleic acid (RNA) at the IC date~4. Admitted as inpatient to a hospital with radiologically confirmed pneumonia~5. Severe form of COVID-19.~6. Subjects meeting any of the following criteria:~   * Total respiratory rate \> 30 breaths per minute~  * SpO2 ≤ 93%~  * PaO2 /FiO2 ≤ 300 mmHg~  * Chest imaging (X-ray, CT, US) showed lesion progression within 24-48 hours \>50%~  * Decrease of consciousness level, Psychomotor agitation/irritability~  * Hemodynamically unstable (systolic blood pressure \<90 mmHg or diastolic blood pressure \< 60 mmHg or urine output \< 20 ml/h)~  * Arterial lactate \> 2 mmol/l~  * qSOFA (quick sequential organ failure assessment score) \> 2. Subjects meeting three following criteria: Low blood pressure (SBP ≤ 100 mmHg); High respiratory rate (≥ 22 breaths/min); Altered mentation (Glasgow Coma Scale ≤ 14)~Exclusion Criteria:~1. Critical COVID-19. Subjects meeting any of the following:~   * Respiratory failure and requiring invasive mechanical ventilation (tracheal intubation)~  * Septic shock~  * Multiple organ failure~2. Life expectancy \< 24h, in the opinion of the investigator,~3. Unlikely to remain at the investigational site beyond 48 hours~4. Use of other monoclonal antibodies for COVID-19 treatment~5. Current treatment with immunosuppressive agents (including corticosteroids)~6. Participating in other drug clinical trials at the IC date or within 60 days after randomization (participation in COVID-19 anti-viral trials may be permitted if approved by Sponsor)~7. Laboratory values:~   * ALT / AST \> 10 ULN at screening~  * Platelets \< 50х109/l at screening~  * Absolute Neutrophil Count \< 1х109/l at screening~8. Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)~9. Confirmed active tuberculosis~10. History of allergic reaction to monoclonal antibodies~11. Pregnancy or breastfeeding~12. Any illness or laboratory findings that, in the opinion of the study investigator, might pose an additional risk to the patient by their participation in the study,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LVL group (Type: EXPERIMENTAL): Single subcutaneous administration of levilimab at a dose of 324 mg in combination with standard therapy
- Placebo group (Type: PLACEBO_COMPARATOR): Single subcutaneous administration of placebo in combination with standard therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete